New Rheumatoid Arthritis Drug

Roche wins expanded US approval for rheumatoid arthritis treatment.
Bloomberg News (1/6, Doherty) reports, "Roche Holding AG's Actemra (tocilizumab) medicine won expanded US approval as a treatment for moderate to severe rheumatoid arthritis." Actemra "can be used to inhibit and slow structural joint damage and improve physical function when combined with a standard medicine, methotrexate," Roche said. Actemra "won US clearance last year as a therapy for rheumatoid arthritis patients who haven't been helped by older treatments."